Bristol Myers Squibb Company’s Istodax (romidepsin) is the first anti-cancer drug outside the PD-1/L1 class to lose an accelerated approval indication under the US Food and Drug Administration’s recent initiative to remove “dangling” claims from labeling when confirmatory trials fail.
On 2 August, BMS announced it would withdraw Istodax’s indication for second-line treatment of peripheral T-cell lymphoma (PTCL) because a...






